Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography

Sponsor
Planmed Oy (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT00942396
Collaborator
(none)
250
2
1
35
125
3.6

Study Details

Study Description

Brief Summary

Evaluate the diagnostic accuracy of the Planmed Sophie Nuance Full Field Digital Mammography (FFDM) X-ray System compared to screen-film mammography (SFM) in the detection of breast cancer.

Condition or Disease Intervention/Treatment Phase
  • Device: Full Field Digital Mammogram (Planmed Sophie Nuance)
Phase 3

Detailed Description

Objectives: 1) To establish the non-inferiority of the diagnostic accuracy of the Planmed Sophie Nuance Full Field Digital Mammography (FFDM) X-ray System compared to screen-film mammography (SFM) in the detection of breast cancer; and 2) To demonstrate in a comparative side-by-side feature analysis that interpretations based on the Planmed Sophie Nuance FFDM X-ray System are diagnostically non-inferior to SFM in the detection of breast cancer.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
250 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography
Study Start Date :
Apr 1, 2008
Anticipated Primary Completion Date :
Mar 1, 2011
Anticipated Study Completion Date :
Mar 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: mammography

Women must be at least 40 years of age, presenting for routine breast cancer screening or presenting with one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography

Device: Full Field Digital Mammogram (Planmed Sophie Nuance)
Full Field Digital Mammogram
Other Names:
  • mammography
  • digital mammography
  • Outcome Measures

    Primary Outcome Measures

    1. Area under ROC curve based on subjects' maximum POM scores; sensitivity based on subjects' maximum BI-RADS scores with 4 or higher as positive for cancer; and specificity based on subjects maximum BI-RADS scores with 4 or higher as positive for cancer [Approximately one year after completion of study.]

    Secondary Outcome Measures

    1. area under the ROC curve based on the maximum POM score per subject-breast [Approximately one year after completion of study.]

    2. area under the ROC curve based on the POM scores from the ten regions of a subject's breasts; [Approximately one year after completion of study.]

    3. sensitivity based on subjects' maximum BI-RADS scores using a cut-point of 3 or higher as positive for cancer; [Approximately one year after completion of study.]

    4. specificity based on subjects' maximum BI-RADS scores using a cut-point of 3 or higher as positive for cancer; [Approximately one year after completion of study.]

    5. Sensitivity and specificity based on the maximum BI-RADS scores per subject-breast using 4 or higher for positive; and sensitivity and specificity based on the maximum BI-RADS scores per subject-breast using 3 or higher for positive. [Approximately one year after completion of study.]

    6. Feature Analysis Study; side by side assessment of SFM and FFDM images and comparison of quality features: lesion conspicuity, tissue visibility at chest wall, tissue visibility at skin line, axillary details (MLO), overall contrast, overall sharpness [Approximately one year after completion of study.]

    7. Adverse event assessment [Approximately 24 hours after completion of FFDM]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 85 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Subject is 40 years of age or older

    2. Subject is presenting for routine breasts cancer screening (Cohort I) OR Subject has one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography (Cohort II)

    3. Subject's schedule permits the SFM and the FFDM to be performed no more than 30 days apart and with no intervention between the exams

    4. Subject will provide prospective, written informed consent

    5. Subject is considered capable of complying with study procedures including a willingness to return for a one-year follow-up exam -

    Exclusion Criteria:
    1. Subject is pregnant or possibly pregnant or planning pregnancy within the next 15 months

    2. Subject has undergone a breast augmentation or breast implant? Has subject had any of the following breast procedures?

    Fine needle or cyst aspiration NOT Eligible if within past year Biopsy Not Eligible if within past year Lumpectomy (for breast cancer) Mastectomy (for breast cancer) Radiation therapy Breast reconstruction Breast reduction Not Eligible if within past year

    1. Subject has had an invasive breast procedure or operation within the past year

    2. Subject has significant existing breast trauma

    3. Subject has a history of breast cancer treated with operation or radiation

    4. Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mroz-Baier Breast Care Clinic Memphis Tennessee United States 38119
    2 The Rose Houston Texas United States 77034

    Sponsors and Collaborators

    • Planmed Oy

    Investigators

    • Study Director: Sami Tohka, PhD, Planmed Oy

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00942396
    Other Study ID Numbers:
    • TK01007
    First Posted:
    Jul 20, 2009
    Last Update Posted:
    Jun 9, 2011
    Last Verified:
    Jun 1, 2011
    Keywords provided by , ,

    Study Results

    No Results Posted as of Jun 9, 2011